Old Well Partners’s Climb Bio CLYM Stock Holding History

Old Well Partners’s Portfolio CLYM Stock Details CLYM Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2022 Q1	–	Sell	-10,300	Closed	-$108K	–	45
2021 Q4	$108K	Buy	+10,300	New	+$154K	0.07%	39

Other funds holding CLYM

RCM

RA Capital Management Boston, Massachusetts $9.44B AUM 157.3% 1-Year Est. Return

Samlyn Capital New York $5.86B AUM 36.3% 1-Year Est. Return

Woodline Partners San Francisco, California $26.4B AUM 44.85% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

MIM

Monashee Investment Management Boston, Massachusetts $184M AUM 197.43% 1-Year Est. Return

Goldman Sachs New York $871B AUM 31.28% 1-Year Est. Return

Point72 Asset Management Stamford, Connecticut $78.1B AUM 55.25% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

Hudson Bay Capital Management Stamford, Connecticut $29B AUM 30.2% 1-Year Est. Return

Old Well Partners's CLYM Position: Q1 2022 in Review

Old Well Partners sold out of Climb Bio (CLYM) in Q1 2022, closing a stake of 10,300 shares — an estimated $108K sold.

Old Well Partners first reported a position in CLYM in Q4 2021 and held it in 1 quarter. The position peaked at $108K in Q4 2021. 43 funds tracked by Wall St. Rank hold CLYM as of Q1 2022.

Old Well Partners reported no remaining Climb Bio position as of Q1 2022 after selling out during the quarter.
Old Well Partners sold 10,300 Climb Bio shares in Q1 2022, an estimated $108K.
Old Well Partners first reported a position in Climb Bio in Q4 2021 and held it in 1 quarter.
Old Well Partners's Climb Bio position peaked at $108K in Q4 2021.
43 funds tracked by Wall St. Rank held Climb Bio as of Q1 2022.

Based on Old Well Partners's 13F filing for Q1 2022, filed 16 May 2022.